The study’s latest data shows that patients on ventilators who received baricitinib plus standard care were 46% less likely to die than those who received placebo plus standard care.
On Tuesday, Eli Lilly and Incyte Corp (INCY.O) announced that their COVID-19 drug baricitinib reduced the risk of death in patients on mechanical ventilation.
The FDA first approved Lilly’s baricitinib combined with Gilead Sciences’ (GILD.O) remdesivir to treat COVID-19 patients.
The FDA last month approved the drug alone or with remdesivir.
- Neuroscience Breakthrough: Study Pinpoints Brain Activity That Helps Prevent Us From Getting Lost
- Brief Anger Hampers Blood Vessel Function Leading to Increased Risk of Heart Disease and Stroke – New Study
- New Blood Test Pinpoints Future Stroke Risk – Study Identifies Inflammatory Molecules as Key Biomarker
- Enceladus: A Potential Haven for Extraterrestrial Life in its Hidden Ocean Depths
- New Experiment: Dark Matter Is Not As ‘DARK’ As All We Think
The study’s latest data shows that patients on ventilators who received baricitinib plus standard care were 46% less likely to die than those who received placebo plus standard care.
Lilly said the study’s findings will be shared with regulatory agencies in the US, EU, and elsewhere.
Source: Reuters
Image Credit: Getty